Predicta Biosciences

Comprehensive overview of test methodology, clinical utility, and evidence base

Predicta Biosciences offers biopharma partners a platform for deeper molecular insights from a single blood draw, combining whole-genome sequencing, cellular analytics, and longitudinal disease monitoring.

Presented at the International Myeloma Society congress, demonstrating high analytical concordance between blood and bone marrow and confirming the platform’s readiness for routine clinical use.

EloLenDex is linked to an 89% 4-year progression-free survival rate in high-risk smoldering multiple myeloma patients. Higher cytotoxic T cell abundance and immune normalization post-therapy correlate with longer progression-free survival.

Presented at the American Society of Hematology annual meeting, demonstrating GenoPredicta’s ability to identify genomic resistance mechanisms from both sample types with clinical-grade sensitivity.

The foundational study establishing whole-genome sequencing of intact circulating tumor cells from peripheral blood as a clinically viable approach to comprehensive myeloma characterization - including at minimal disease burden.

Follow the progress of Predicta Biosciences through company announcements, funding milestones, product launches, scientific discoveries, and industry insights focused on transforming the diagnosis and treatment of complex diseases.

Predicta Biosciences launched GenoPredicta, a Laboratory Developed Test for bone marrow or blood that detects genomic alterations in patients with or at risk of hematologic malignancies.

Modern blood cancer care demands more than a diagnostic result. As patients live longer and therapies become increasingly personalized, physicians need continuous insight into disease biology, immune response, and treatment effectiveness.

Predicta Biosciences develops a molecular insights platform for blood cancer care, using a single blood sample to provide genomic and immune data for disease monitoring and treatment guidance.